Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer

Background: While numerous susceptibility loci for epithelial ovarian cancer (EOC) have been identified, few associations have been reported with overall survival. In the absence of common prognostic genetic markers, we hypothesize that rare coding variants may be associated with overall EOC survival and assessed their contribution in two exome-based genotyping projects of the Ovarian Cancer Association Consortium (OCAC).

Methods: The primary patient set (Set 1) included 14 independent EOC studies (4,293 patients) and 227,892 variants, and a secondary patient set (Set 2) included six additional EOC studies (1,744 patients) and 114,620 variants. Because power to detect rare variants individually is reduced, gene-level tests were conducted. Sets were analyzed separately at individual variants and by gene, and then combined with meta-analyses (73,203 variants and 13,163 genes overlapped).

Results: No individual variant reached genome-wide statistical significance. A SNP previously implicated to be associated with EOC risk and, to a lesser extent, survival, rs8170, showed the strongest evidence of association with survival and similar effect size estimates across sets (Pmeta = 1.1E-6, HRSet1 = 1.17, HRSet2 = 1.14). Rare variants in ATG2B, an autophagy gene important for apoptosis, were significantly associated with survival after multiple testing correction (Pmeta = 1.1E-6; Pcorrected = 0.01).

Conclusions: Common variant rs8170 and rare variants in ATG2B may be associated with EOC overall survival, although further study is needed.

Impact: This study represents the first exome-wide association study of EOC survival to include rare variant analyses, and suggests that complementary single variant and gene-level analyses in large studies are needed to identify rare variants that warrant follow-up study. Cancer Epidemiol Biomarkers Prev; 25(3); 446-54. ©2016 AACR.

Citing Articles

Polymorphisms in autophagy genes are genetic susceptibility factors in glioblastoma development.

Bueno-Martinez E, Lara-Almunia M, Rodriguez-Arias C, Otero-Rodriguez A, Garfias-Arjona S, Gonzalez-Sarmiento R BMC Cancer. 2022; 22(1):146.

PMID: 35123435 PMC: 8818195. DOI: 10.1186/s12885-022-09214-y.

Biologic Mechanisms Linked to Prognosis in Ovarian Cancer that May Be Affected by Aging.

Chon H, Sehovic M, Marchion D, Walko C, Xiong Y, Extermann M J Cancer. 2019; 10(12):2604-2618.

PMID: 31258768 PMC: 6584919. DOI: 10.7150/jca.29611.

Molecular signatures of X chromosome inactivation and associations with clinical outcomes in epithelial ovarian cancer.

Winham S, Larson N, Armasu S, Fogarty Z, Larson M, McCauley B Hum Mol Genet. 2018; 28(8):1331-1342.

PMID: 30576442 PMC: 6625007. DOI: 10.1093/hmg/ddy444.

An integrative approach to assess X-chromosome inactivation using allele-specific expression with applications to epithelial ovarian cancer.

Larson N, Fogarty Z, Larson M, Kalli K, Lawrenson K, Gayther S Genet Epidemiol. 2017; 41(8):898-914.

PMID: 29119601 PMC: 5726546. DOI: 10.1002/gepi.22091.

References

Song H, Ramus S, Tyrer J, Bolton K, Gentry-Maharaj A, Wozniak E . A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet. 2009; 41(9):996-1000. PMC: 2844110. DOI: 10.1038/ng.424. View

Madsen B, Browning S . A groupwise association test for rare mutations using a weighted sum statistic. PLoS Genet. 2009; 5(2):e1000384. PMC: 2633048. DOI: 10.1371/journal.pgen.1000384. View

Eichler E, Flint J, Gibson G, Kong A, Leal S, Moore J . Missing heritability and strategies for finding the underlying causes of complex disease. Nat Rev Genet. 2010; 11(6):446-50. PMC: 2942068. DOI: 10.1038/nrg2809. View

Antoniou A, Wang X, Fredericksen Z, McGuffog L, Tarrell R, Sinilnikova O . A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet. 2010; 42(10):885-92. PMC: 3130795. DOI: 10.1038/ng.669. View

Goode E, Chenevix-Trench G, Song H, Ramus S, Notaridou M, Lawrenson K . A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet. 2010; 42(10):874-9. PMC: 3020231. DOI: 10.1038/ng.668. View

Bolton K, Tyrer J, Song H, Ramus S, Notaridou M, Jones C . Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet. 2010; 42(10):880-4. PMC: 3125495. DOI: 10.1038/ng.666. View

Neale B, Rivas M, Voight B, Altshuler D, Devlin B, Orho-Melander M . Testing for an unusual distribution of rare variants. PLoS Genet. 2011; 7(3):e1001322. PMC: 3048375. DOI: 10.1371/journal.pgen.1001322. View

Wu M, Lee S, Cai T, Li Y, Boehnke M, Lin X . Rare-variant association testing for sequencing data with the sequence kernel association test. Am J Hum Genet. 2011; 89(1):82-93. PMC: 3135811. DOI: 10.1016/j.ajhg.2011.05.029. View

Li L, Li Y, Browning S, Browning B, Slater A, Kong X . Performance of genotype imputation for rare variants identified in exons and flanking regions of genes. PLoS One. 2011; 6(9):e24945. PMC: 3176314. DOI: 10.1371/journal.pone.0024945. View

10.

Bolton K, Chenevix-Trench G, Goh C, Sadetzki S, Ramus S, Karlan B . Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA. 2012; 307(4):382-90. PMC: 3727895. DOI: 10.1001/jama.2012.20. View

11.

Fridley B, Jenkins G, Tsai Y, Song H, Bolton K, Fenstermacher D . Gene set analysis of survival following ovarian cancer implicates macrolide binding and intracellular signaling genes. Cancer Epidemiol Biomarkers Prev. 2012; 21(3):529-36. PMC: 3297690. DOI: 10.1158/1055-9965.EPI-11-0741. View

12.

Couch F, Gaudet M, Antoniou A, Ramus S, Kuchenbaecker K, Soucy P . Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2012; 21(4):645-57. PMC: 3319317. DOI: 10.1158/1055-9965.EPI-11-0888. View

13.

Stevens K, Fredericksen Z, Vachon C, Wang X, Margolin S, Lindblom A . 19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res. 2012; 72(7):1795-803. PMC: 3319792. DOI: 10.1158/0008-5472.CAN-11-3364. View

14.

Kovaleva V, Mora R, Park Y, Plass C, Chiramel A, Bartenschlager R . miRNA-130a targets ATG2B and DICER1 to inhibit autophagy and trigger killing of chronic lymphocytic leukemia cells. Cancer Res. 2012; 72(7):1763-72. DOI: 10.1158/0008-5472.CAN-11-3671. View

15.

Nickells R . The cell and molecular biology of glaucoma: mechanisms of retinal ganglion cell death. Invest Ophthalmol Vis Sci. 2012; 53(5):2476-81. PMC: 3990459. DOI: 10.1167/iovs.12-9483h. View

16.

Fu W, OConnor T, Jun G, Kang H, Abecasis G, Leal S . Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. Nature. 2012; 493(7431):216-20. PMC: 3676746. DOI: 10.1038/nature11690. View

17.

Yang X, Zhong X, Tanyi J, Shen J, Xu C, Gao P . mir-30d Regulates multiple genes in the autophagy pathway and impairs autophagy process in human cancer cells. Biochem Biophys Res Commun. 2013; 431(3):617-22. PMC: 3578012. DOI: 10.1016/j.bbrc.2012.12.083. View

18.

Pharoah P, Tsai Y, Ramus S, Phelan C, Goode E, Lawrenson K . GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet. 2013; 45(4):362-70, 370e1-2. PMC: 3693183. DOI: 10.1038/ng.2564. View

19.

Bojesen S, Pooley K, Johnatty S, Beesley J, Michailidou K, Tyrer J . Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet. 2013; 45(4):371-84, 384e1-2. PMC: 3670748. DOI: 10.1038/ng.2566. View

20.

White K, Vierkant R, Fogarty Z, Charbonneau B, Block M, Pharoah P . Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome. Cancer Epidemiol Biomarkers Prev. 2013; 22(5):987-92. PMC: 3650102. DOI: 10.1158/1055-9965.EPI-13-0028. View